Topic

Articles

More opinions enter the mix as EU launches legislation review.

Europe’s Drug  Pricing Conundrums Coming to a Head

 and can be reached at mhollan@mjhlifesciences.com.

The UK BioIndustry Association and Clarivate detail current economic trends in the UK Biotech Financing Report.

New Reports Reveals Economic Challenges For Life Sciences Industry

Bruce Liu is a partner at Simon-Kucher & Partners, leading its life sciences division in greater China.

The time is ripe to double down on local “market-fit” capabilities.

Seizing On Asia’s Opportune Market for Novel Vaccines

US pharma industry handcuffed by restrictions, group argues. 

European Policy Called Out as Threat to Drug Trade and Investment

Justinian Liu is a senior consultant for Simon-Kucher.

Duo Xu is a senior consultant for Simon-Kucher.

Shiying He is a senior consultant for Simon-Kucher.

Selene Peng is a senior consultant for Simon-Kucher.

Despite the twists and turns, 2022 turned out to be a banner year for National Reimbursement Drug List’s new inclusions—and with welcomed upgrades to bidding and renewal rules.    

China’s 2022 NRDL Readout

An ecosystem perspective is the first step.

Innovating the Go-to-Market Model in Asia 

Incyte Biosciences United Kingdom and Ireland Appoints Peter Williams As General Manager

Commercial Health Insurance may bring more opportunities for market access in China.

The Emergence of Commercial Health Insurances as an Access Route to the Chinese Market

Global go-to-market strategies in region require a revamped gameplan.

Cracking the Code to Commercial Promise in Asia 

The 2022 National Reimbursement Drug List will see more pressures for new inclusions on the one hand, and more certainties for renewals on the other. At the same time, the process is becoming more interactive and transparent.